Akero Therapeutics, Inc.
AKRO
Clasificación en acciones
#3728
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Precio por acción
$54.65
Última sincronización: 2025-12-09
Capitalización bursátil
$4.50B
Cambio (1 día)
0.00%
Cambio (1 año)
1.50%
País
US
Comercio Akero Therapeutics, Inc. (AKRO)
Categoría
Healthcare
EPS de Akero Therapeutics, Inc. (AKRO)
EPS a fecha de September 2025 TTM: $-3.74
Según los últimos informes financieros y el precio de las acciones de Akero Therapeutics, Inc., el EPS actual de la empresa (TTM) es $-3.74. Al final del año 2023, la empresa tenía un EPS de $-2.89 un aumento con respecto a al EPS de 2022, que fue de $-2.87.
Historial de EPS de Akero Therapeutics, Inc. desde 2017 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-3.74 | -0.27% |
| 2024 | $-3.75 | 29.76% |
| 2023 | $-2.89 | 0.70% |
| 2022 | $-2.87 | -0.69% |
| 2021 | $-2.89 | 14.68% |
| 2020 | $-2.52 | -13.10% |
| 2019 | $-2.90 | -24.68% |
| 2018 | $-3.85 | 2,306.25% |
| 2017 | $-0.16 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -563.10% |
US
|
|
| $-7.98 | 113.37% |
US
|
|
| $-5.29 | 41.44% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -841.71% |
NL
|
